↓ Skip to main content

American Association for Cancer Research

Article Metrics

Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States

Overview of attention for article published in Cancer Epidemiology, Biomarkers & Prevention, May 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#16 of 3,989)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
52 news outlets
blogs
2 blogs
policy
1 policy source
twitter
187 tweeters
patent
1 patent
facebook
16 Facebook pages

Citations

dimensions_citation
190 Dimensions

Readers on

mendeley
220 Mendeley
citeulike
1 CiteULike
Title
Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States
Published in
Cancer Epidemiology, Biomarkers & Prevention, May 2017
DOI 10.1158/1055-9965.epi-16-0889
Pubmed ID
Authors

Angela B. Mariotto, Ruth Etzioni, Marc Hurlbert, Lynne Penberthy, Musa Mayer

Abstract

Background: Distant metastatic breast cancer (MBC), including metastases found at diagnosis (de novo) and those occurring later (recurrence), represents the most severe form of the disease, when resource utilization is most intensive. Yet, the number of women living with MBC in the United States is unknown. The objective of this article is to use population-based data to estimate the prevalence of MBC.Methods: We used a back-calculation method to estimate MBC prevalence from U.S. breast cancer mortality and survival from the Surveillance, Epidemiology and End Results (SEER) registries. On the basis of the illness-death process, this method assumes that each observed breast cancer death is the result of MBC, either de novo or a recurrence with metastatic disease.Results: We estimate that by January 1, 2017, there will be 154,794 women living with MBC in the United States, three in four initially diagnosed with stage I-III breast cancer who later progressed to MBC.Median survival and 5-year relative survival for de novo MBC increased over the years, especially in younger women. We estimate a two-fold increase in 5-year relative survival rate from 18% to 36%, for women diagnosed with de novo MBC at age 15-49 between 1992-1994 and 2005-2012, respectively.Conclusions: This study demonstrates an increasing number of women in the United States living with MBC, likely the result of improvements in treatment and aging of the U.S. Impact: The increasing burden of MBC highlights the importance of documenting recurrence to foster more research into the specific needs of this understudied population. Cancer Epidemiol Biomarkers Prev; 1-7. ©2017 AACR.

Twitter Demographics

The data shown below were collected from the profiles of 187 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 220 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 220 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 33 15%
Student > Master 32 15%
Researcher 30 14%
Other 26 12%
Student > Bachelor 17 8%
Other 43 20%
Unknown 39 18%
Readers by discipline Count As %
Medicine and Dentistry 61 28%
Agricultural and Biological Sciences 25 11%
Biochemistry, Genetics and Molecular Biology 24 11%
Engineering 12 5%
Nursing and Health Professions 8 4%
Other 42 19%
Unknown 48 22%

Attention Score in Context

This research output has an Altmetric Attention Score of 552. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 June 2021.
All research outputs
#23,828
of 17,954,410 outputs
Outputs from Cancer Epidemiology, Biomarkers & Prevention
#16
of 3,989 outputs
Outputs of similar age
#686
of 275,661 outputs
Outputs of similar age from Cancer Epidemiology, Biomarkers & Prevention
#2
of 102 outputs
Altmetric has tracked 17,954,410 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,989 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.4. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 275,661 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 102 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.